deltatrials
Completed OBSERVATIONAL NCT04000776

3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer

Triple-tracer Molecular Imaging Using 18F-FDG, 68Ga-PSMA and 68Ga-OCTREOTATE to Characterize Metastatic Castration-resistant Prostate Cancer (mCRPC) and Evaluate Eligibility for Radionuclide Therapies

Sponsor: Canadian Cancer Society (CCS)

Conditions Metastatic Castration-resistant Prostate Cancer
Interventions FDG Positron emission tomography (PET) scan OCTREOTATE Positron emission tomography (PET) scan Optional Bone or soft-tissue biopsies PSMA Positron emission tomography (PET) scan
Updated 13 times since 2019 Last updated: Aug 25, 2023 Started: Dec 16, 2019 Primary completion: Mar 30, 2023 Completion: Jun 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Metastatic Castration-resistant Prostate Cancer and is currently completed. Canadian Cancer Society (CCS) leads this study, which shows 13 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2019 – ~Feb 2020 · 7 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Nov 2020 · 8 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~Aug 2023 · 11 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Sep 2023 — Jul 2024 [monthly]

    Completed

    Status: Active Not Recruiting → Completed

  5. Aug 2023 — Sep 2023 [monthly]

    Active Not Recruiting

▶ Show 8 earlier versions

  1. Sep 2022 — Aug 2023 [monthly]

    Active Not Recruiting

    Status: Recruiting → Active Not Recruiting

  2. Dec 2021 — Sep 2022 [monthly]

    Recruiting

  3. Sep 2021 — Dec 2021 [monthly]

    Recruiting

  4. Jan 2021 — Sep 2021 [monthly]

    Recruiting

  5. Nov 2020 — Jan 2021 [monthly]

    Recruiting

  6. Mar 2020 — Nov 2020 [monthly]

    Recruiting

  7. Feb 2020 — Mar 2020 [monthly]

    Recruiting

    Status: Not Yet Recruiting → Recruiting

  8. Jul 2019 — Feb 2020 [monthly]

    Not Yet Recruiting

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Canadian Cancer Society (CCS)
  • Fonds de la Recherche en Santé du Québec
  • Merck Canada Inc.
  • Oncopole
  • Université de Sherbrooke
Data source: Université de Sherbrooke

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations